Using an experimental mouse model, we have investigated the kinetics of hematopoietic reconstitution of recipients transplanted during fetal development with fresh and transduced hematopoietic stem cells (HSCs). Total bone marrow (BM) and purified Lin À Sca-1 + cells, either fresh or transduced ex vivo with enhanced green fluorescent protein (EGFP)-encoding retroviral vectors, were in utero transplanted (IUT) into fetal mice. Data obtained 2 months after transplantation showed a similar proportion of engrafted animals, regardless of the fact that samples were purified or not on HSCs, and subjected or not to ex vivo transduction with retroviral vectors. The transplantation of grafts enriched in HSCs, either fresh or transduced, always improved the levels of donor chimerism of IUT mice in comparison with results obtained in mice transplanted with unpurified BM grafts (6.8 and 7.3% versus 1.15% median values, respectively). Significantly, engrafted recipients that were transplanted with the transduced graft always contained transduced EGFP + cells in peripheral blood (around 5% of donor cells were EGFP + at 2 months post-transplantation). This proportion was essentially maintained at longer times post-transplantation, as well as in secondary recipients transplanted with the BM of IUT mice. Our study describes for the first time a significant and stable engraftment of unconditioned mice subjected to IUT with HSCs transduced with retroviral vectors.
Introduction
The possibility of treating genetically inherited diseases before birth constitutes an attractive therapeutic approach, particularly in those cases in which the severity of the disease progresses rapidly during the early stages of growth.
As considered in the case of adult patients, allogeneic in utero transplantation (IUT) of hematopoietic stem cells (HSCs) has been suggested in a number of genetic diseases, not only in experimental models 1, 2 but also in human patients. 3 Unlike postnatal transplantation, IUT does not require the myeloablation of the patient, given that in the former case transplanted cells can home into preimmune hematopoietic tissues undergoing massive expansion. 4 In spite of this advantage, very low levels of chimerism generally take place in these recipients, unless donor-transplanted cells develop a strong selective advantage over the endogenous cells. 3, 5, 6 Aiming to improve the chimerism associated with this transplantation modality, three main experimental approaches have been proposed: (1) cotransplantation of donor-immunocompetent cells together with the donor HSCs, 7 (2) cotransplantation of donor stromal and HSCs, 8 and (3) transplantation of high numbers of purified donor HSCs. 9, 10 Additionally, donor-immunocompetent cells have also been infused after the birth of IUT recipients to promote the expansion of donor hematopoietic cells in the recipient. 11, 12 The progressive development of gene therapy tools for the treatment of several genetic diseases has also evolved into the study of gene therapy approaches aiming at the treatment of patients during their fetal stages of development. In this context, two main strategies have been considered: as described for adult patients, protocols based on the transplantation of genetically corrected autologous HSCs have been proposed in the context of IUT. 13 Additionally, strategies based on the direct inoculation of the therapeutic vector in the fetal tissues have also been investigated. [14] [15] [16] While the first approach prevents the transduction of nondesired tissues (ie germinal cells), the direct inoculation of the vector into the recipient tissues limits the generation of undesired effects produced as a result of the ex vivo manipulation and transplantation of the target population (ie the HSCs). In spite of the interest of all the therapeutic approaches mentioned above, most of them are highly experimental, and further improvements are required before they could be considered for the treatment of patients diagnosed from their disease during the prenatal stages of growth.
Using an experimental mouse model, we have investigated the long-term engraftment of recipient mice that were transplanted during their fetal development with congenic bone marrow (BM) grafts, subjected or not to HSC enrichment. Additionally, HSCs were also transduced ex vivo with retroviral vectors and then transplanted intra-utero, aiming to investigate the influence that the genetic manipulation of the sample had on the level of engraftment of the transduced HSCs. Our study describes for the first time a significant engraftment of unconditioned mice that had been subjected to in utero transplantation with congenic HSCs efficiently transduced with retroviral vectors.
Results
Engraftment of mice after intra-utero transplantation of fresh and transduced BM cells
In these experiments, a total of 138 fetal Ly5.2 mice were transplanted intra-utero with donor cells derived from congenic mice expressing the Ly5.1 panleukocytary marker to facilitate the recognition of donor hematopoietic cells in the peripheral blood (PB) of recipients.
Initially, we investigated the efficiency of engraftment associated with the transplantation of fetal mice with grafts consisting of 5 million BM cells (BMCs) and with equivalent samples consisting of 20 000 purified Lin À Sca-1 + cells. As shown in Table 1 , the survival rate following transplantation of large unpurified grafts was slightly lower compared to the transplantation of small samples of purified Lin À Sca-1 + cells (39 versus 49%) mainly because of methodological aspects. Engrafted animals were defined as those containing at least 0.5% of donor Ly5.1 cells in the PB of recipients 8 weeks after the IUT of fetal mice (see representative analyses of engraftment in Figure 1a ). As indicated in Table 1 , the proportion of engrafted animals was slightly higher in recipients that received unpurified BMCs (46 versus 31%, respectively). When the percentages of survival and of engraftment were considered together, a similar proportion of engrafted versus transplanted animals was obtained when 5 million BMCs or 20 000 purified Lin À Sca-1 + cells were transplanted (18 and 15% of the IUT mice were, respectively, engrafted by donor cells).
To investigate whether the genetic manipulation of donor stem cells mediated any impairment in the in utero engraftment capability of the samples, Lin À Sca-1 + cells were transduced with retroviral vectors encoding the enhanced green fluorescent protein (EGFP) marker and then IUT into fetal mice. As shown in Table 1 , the viability of fetal mice that were transplanted with Assuming that the probability for engrafting a recipient with each of these three samples is similar, we searched for potential differences in the level of chimerism achieved in the different recipient groups. As shown in Table 1 , while engrafted animals that were transplanted with 5 Â 10 6 BMCs contained a median value of 1.15% of donor cells in PB (highest engraftment: 6.2%), this value increased to a median value of 6.8% in recipients transplanted with fresh Lin These data indicate that although the proportion of engrafted animals is similar in the different groups of transplanted mice, the level of chimerism that is achieved in the engrafted animals is significantly higher when 2 Â 10 4 purified Lin À Sca-1 + cells are transplanted, when compared to 5 Â 10 6 unpurified BMC (Po0.05). Moreover, our data indicate that the ex vivo manipulation required for the retroviral transduction of the graft does not modify the repopulating properties of the sample after IUT transplantation.
Since the ex vivo manipulation of the sample may have preserved the short-term repopulating properties of the graft, but impaired the functionality of the long-term repopulating cells, we followed the level of chimerism of recipients transplanted with genetically manipulated grafts in the long term. As shown in Figure 1b , the level of chimerism observed in four different animals (2.17, 2.11, 2.8 and 1.5) progressively increased throughout the post-transplantation period of analysis (6 months). In three animals (2.20, 2.12 and 1.3), the chimerism was essentially maintained, and in one animal (2.15), the chimerism was decreased in the last two analyses. Routine Ly5.1 analysis conducted in the different hematopoietic lineages confirmed the repopulation of donor cells both in the myeloid and lymphoid lineages (see representative analyses in Figure 1c ). Taken together, we conclude the efficient and long-term engraftment of IUT mice with samples manipulated under conditions required for their transduction with retroviral vectors.
Engraftment of in utero transplanted mice with genetically transduced hematopoietic stem cells
To investigate the stability of engraftment of recipient mice with genetically transduced cells, the proportion of EGFP + cells in the eight animals that were engrafted with donor Ly5.1 cells (see Table 1 ) was determined at different times post-transplantation. Significantly, in all these animals we could detect the presence of donor cells that expressed the marker transgene (see a representative analysis in Figure 2a Additional analyses conducted at 90 and 180 days post-transplantation (white bars in Figure 2 ) indicated that the proportion of Ly5.1 + cells that expressed the marker transgene was essentially stable in four animals (2.15, 2.8, 1.5, 1.3) out of the eight engrafted mice. In two animals, the proportion of Ly5.1 + cells that were EGFP + decreased along time (2.20, 2.12), and in two mice this proportion increased (2.17, 2.11) over the post-transplantation period (Figure 2b ). To further confirm that very primitive repopulating cells had been transduced and contributed to the engraftment of IUT mice, BMC from primary recipients were transplanted into secondary Ly5.2 recipients (two aliquots of 10 7 BMCs were each transplanted into two secondary recipients). At 60 days after transplantation, the proportion of EGFP + cells in Ly5.1 cells was again investigated by flow cytometry. Data corresponding to secondary recipients are also represented in Figure 2b (dark bars). As shown in the figure, the proportion of donor Ly5.1 cells that expressed the EGFP transgene in secondary recipients was maintained or decreased with respect to primary recipients in four cases (mice 2.17, BMC from a primary recipient. Each bar corresponds to a single secondary recipient mouse (two secondary recipients were transplanted in each case, both of which were analyzed at 60 days post-transplant). 
Discussion
In this study, we describe the influence that the purification and the ex vivo transduction of mouse HSCs has on the survival and the engraftment of congenic mice transplanted during fetal development. In addition, the stability of transgene expression associated with the IUT of transduced HSCs has been investigated long-term after transplantation. Previous studies showed that the level of engraftment of preimmune fetal mice transplanted with allogeneic and syngenic or congenic grafts was similar. 17 Using the same model of Ly5.1 and Ly5.2 congenic mice that we used in these experiments, the transplantation of one million BMCs reached a stable level of chimerism that lay between 0.5 and 1.3% in PB. 17 Consistent with these data, we observed that by transplanting five times more BMCs, the proportion of donor hematopoietic cells in the engrafted mice (46% of analyzed recipients) ranged between 1.0 and 6.2%.
Aiming to increase the level of chimerism in recipients subjected to IUT different strategies have been proposed. In the allogeneic IUT model, the highest engraftments have been obtained in approaches involving the cotransplantation of donor lymphocytes, 7 and the use of immunodeficient mice as recipients. 18 In this transplantation modality, the enrichment of HSCs from fetal liver grafts did not improve the engraftment of recipient mice. 19 In our study, we aimed to investigate whether the infusion of purified HSCs would facilitate the engraftment of congenic recipients. Since Lin Based on previous data showing that the ex vivo stimulation or transduction of the HSCs impairs their repopulating potential in adult transplanted recipients, [21] [22] [23] [24] we investigated whether the transduction of purified HSCs was compatible with the engraftment of unconditioned mice transplanted during fetal development. Our data showed not only a very good viability of the IUT mice (65% survival) but also similar or even higher levels of chimerism when compared with animals transplanted with fresh untransduced HSCs. These data clearly indicate that at least under our experimental conditions no detrimental engrafting effects are produced as a result of the ex vivo manipulation of the sample that is required for their transduction with retroviral vectors.
As deduced from Figure 2 our data also demonstrate the reconstitution of the animals with transduced cells that expressed the EGFP marker gene. Restrictions in the long-term engraftment of retrovirally transduced cells that express a marker transgene can occur as a result of the ex vivo manipulation of the HSCs, [21] [22] [23] [24] the immunogenicity of the transgene 25, 26 or the extinction of the transgene expression. 27, 28 Our experiments showed that the proportion of EGFP-expressing cells was essentially maintained not only during sequential analyses of IUT mice but also in mice that were transplanted with the BM of the primary recipients. Consequently, our results indicate that none of the above effects is relevant in our experiments, although of course they may have a role in individual mice in which the levels of engraftment of EGFP + cells was low. Taken together, our results show that very primitive repopulating cells, capable of repopulating the hematopoiesis of primary and secondary recipients, were transduced and engrafted unconditioned fetal mice after in utero transplantation. To our knowledge, this is the first study showing a significant and stable engraftment of ex vivo transduced HSCs that were IUT in congenic recipient mice.
Previous studies have shown the high susceptibility of fetal liver and fetal circulating hematopoietic precursor cells for being transduced with retroviral vectors. 29, 30 In addition, experimental studies with the ovine model showed the possibility of collecting fetal liver cells in sufficient numbers for the autologous transplantation of the animals. 31 The combined use of ex vivo HSC gene therapy and IUT may improve the therapeutic potential of both strategies used as individual therapies, thus facilitating the treatment of diseases diagnosed during fetal development. The possibility of inserting a suicide gene in the transfer vector may facilitate the eradication of the transduced graft in the case that deleterious insertional effects are produced. 32 On the other hand, the use of genes conferring a proliferation advantage in the transduced graft [33] [34] [35] may further facilitate the engraftment of genetically corrected cells in the recipients tissues. These possibilities, together with the investigation of the therapeutical benefits associated with the IUT of grafts transduced with therapeutical vectors, are currently under study in our laboratory using different models of human diseases.
Materials and methods
Mice F1 hybrids of the B6.SJL-PtprcaPep3b/BoyJ and the DBA/2J strains (Ly5.1/Ly5.2 phenotype) were used as donors in all experiments. As recipients, (C57BL/ 6J Â DBA/2J) F1 mice (Ly5.2/Ly5.2 phenotype) were always used. Mice were maintained under high standards conditions (HEPA filtered air, regulated temperature of 221C, light/dark cycle of 12 h, and allowed food 
Preparation of hematopoietic grafts
BMCs were treated with ammonium chloride solution (0.155 mM NH 4 Cl+0.01 mM KHCO 3 +10
À4 mM EDTA) to facilitate the lysis of erythrocytes. A fraction of these cells was resuspended in PBS for the IUT of the animals. A second fraction of lysed cells was subjected to HSC purification. As a first step, Sca-1 + cells were sorted out using the MultiSort Kit (Miltenyi Biotech, Germany) following the manufacturer's recommendations. Briefly, cells were stained with anti Sca-1-FITC for 30 min at 41C, washed with purification buffer 25: (PUB; PBS 1Àx+0.5% BSA) and stained with anti-FITC MultiSort MicroBeads for 15 min at 41C. Cells were subjected to a positive immunomagnetic selection using a column of MS type (Miltenyi Biotech). MACS MultiSort MicroBeads were removed by incubation with MultiSort Release Reagent for 10 min at 6-121C and passed through a second magnetic column to remove unattached magnetic beads. Sca-1 + cells were then stained with a biotinylated cocktail of antibodies recognizing markers of lineage differentiation (anti-CD3, -B220, -Gr-1, -Mac-1, -TER119; all of them from BD Pharmingen, Palo Alto, CA, USA) for 30 min at 41C, washed and incubated again with streptavidin microbeads for 15 min at 6-121C. A third column was finally applied to remove the Lin + cells. Lin 
In utero transplantation
On day 14.5 after mating, pregnant females were anesthetized by intraperitoneal injection of avertin in PBS (0.6 ml/g of body weight 36 ). The abdomen was opened by midline laparatomy and the uterine horns exposed. Each fetus was injected intraperitoneally with 5 Â 10 6 BMCs or with 2 Â 10 4 Lin À Sca-1 + cells in 5 ml of PBS using a 100 mm beveled glass micropipette. Fetuses were rehydrated with PBS and reintroduced into the peritoneal cavity, which was closed using reabsorbable suture (Ethicon PDS II 5/0; Johnson & Johnson, Brussels, Belgium).
Transduction of Lin
À Sca-1 + cells with retroviral vectors Lin À Sca-1 + cells were prestimulated for 48 h in IMDM supplemented with 20% FBS, hrIL-11 and mrSCF (100 ng/ml each, all provided by The Genetics Institute, Cambridge, MA, USA). These culture conditions demonstrated an efficient activation of mouse BM grafts and preservation of the HSC properties of the sample. 37 Prestimulated cells were resuspended at a density of 5 Â 10 4 cells/ml in fresh supernatant supplemented with serum (20% final), growth factors and 5 mg/ml Polybrene. Cells were then added to retronectin-coated wells (retronectin supplied by Takara Shuzo, Otsu, Japan) preloaded 38 with the LFPEG retroviral vector that express the EGFP, kindly provided by H Hanenberg. 39, 40 Supernatant was replaced every 12 h by new viruscontaining medium. A total of four infections were conducted. 39 At 4 h after the last infection cycle, cells were harvested and directly injected into fetuses. On average, 15-30% of EGFP + cells are obtained after transduction under these conditions.
Secondary transplants
Recipients of BM transplants obtained from animals transplanted in utero ((C57BL/6J Â DBA/2J)F1 mice, Ly5.2/Ly5.2 phenotype) were irradiated using a myeloablative regimen (11 Gy fractionated in two doses, 4 h apart) with a Philips MG324 X-ray equipment (Philips, Hamburg, Germany) set at 300 kV, 10 mA, delivered a dose rate of 1.03 Gy/min. In all, 10 million whole BMC from each primary recipient were transplanted into two secondary recipients. At 60 days post-transplantation, blood from these animals was obtained and analyzed for chimerism by flow cytometry.
Analysis of chimerism
Chimerism was evaluated in the peripheral blood from IUT mice (primary recipients) and from secondary recipients. Blood was taken after a small tail vein incision, and chimerism was assessed by flow cytometry, using anti-Ly5.1-PE. A minimum number of 10 
Statistical analysis
The significance of differences between groups was determined by using the Wilcoxon's Mann-Whitney W-test. The processing and statistical analysis of the data was performed by using the Statgraphics Plus 5.0 software package (Manugistics Inc., Rockville, MD, USA).
